The molecular markers of hemostatic activation on coronary artery disease

Thrombosis Research

Volumn 88, Issue 3, 1997, Pages 329-332

  Ulutin, Turgut ^a   Sönmez, Hüseyin ^a   Üçişik, Nergiz ^a   Süer, Selma ^a   Bayram, Çiǧdem ^a   Kökoǧlu, Emine ^a   Sultuybek, Gönül ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

CAD; Hemostatic activation; Molecular markers

Indexed keywords

BETA THROMBOGLOBULIN; BIOCHEMICAL MARKER; D DIMER; FIBRINOPEPTIDE A; FIBRONECTIN; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0344403644     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00262-4     Document Type: Article

References (27)

1. Fareed J, Bick RL, Hoppensteadt DA, Bermes EW Moleuclar markers of hemostatic activation: Applications in the diagnosis of thrombosis and vascular and thrombotic disorders. Clin App Thromb Hemost. 1(2):1995;87-102.
2. Oida K, Maeda H, Nakai T. Abnormal antithrombogenic function on endothelial cells in diabetes mellitus. In: King GL, Shigela Y, editors. Endothelial Cell Dysfunction Diabetes. Japan: Churchill Livingstone; 1994. p. 33-54.
3. Walenga JM, Fareed J, Messmore HL. Newer avenues in the monitoring of antithrombotic therapy: The role of automation. Semin Thromb Hemost 1983;9:346-54.
4. Messmore HL, Walenga JM, Fareed J. Molecular markers of platelet activation. Semin Thromb Hemost 1983;9(4):354-78.
5. Baver KA, Rosenberg RD. The pathophysiology of the prothrombotic state in humans: Insight gained from studies using markers of hemostatic system activation. Blood 1987;70:343-50.
6. Reddy VB, Kowal-Vern A, Hoppensteadt DA, Kumar A, Walenga JM, Fareed J, Schmacher HR Global and molecular hemostatic markers in acute myeloid leukemia. Am J Clin Pathol. 94(4):1990;397-403.
7. Brandtzaeg P, Sandset PM, Joe GB, Ousteloe R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C extrinsic pathway inhibitor and fibrinopeptid A in systemic meningococcal disease. Thromb Res 1989;85:459-70.
8. Fareed J, Walenga JM. Changing trends in hemostatic testing. In: Oukda K, editor. Automation and New Technology in the Clinical Laboratory. Oxford: Oxford Press; 1990. p. 203-10.
9. Süer S, Ulutin T, Sönmez H, Kökoǧlu E, Üçişik N, Bayram Ç, Sultuybek G Plasma Lp(a) and t-PA-PAI-1 complex levels in coronary heart disease. Thromb Res. 83(1):1996;77-85.
10. Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 1994;71:504-7.
11. Sprengers ED, Kloft C. Plasminogen activator inhibitors. Blood 1987;69:381-7.
12. Kruithoff EKO Plasminogen activator inhibitor-1: Biochemical, biological and clinical aspects. Fibronolysis. 2((Suppl 2)):1988;59-70.
13. Loskutoff DJ, Sawdey M, Mimoro J Type 1 plasminogen activator inhibitor. Prog Hemostas Thromb. 9:1988;87-115.
14. Kostner GM, Avogaro P, Lazzolato G, Marth E, Bittolo BG, Qunici GB Lipoprotein (a) and the risk for myocardial infarction. Atherosclerosis. 38:1981;51-61.
15. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) as a risk factor for myocardial infarction. J Am Med Assoc 1986; 256:2540-4.
16. Loscalzo J, Weinfeld M, Fless GM, Scann AM. Lipoprotein (a), fibrin binding and plasminogen activation. Arterosclerosis 1990;10:241-5.
17. Stenman S, Vonsmitten K, Vaheri A. Fibronectin and atherosclerosis. Acta Med Scand 1980;642:165-70.
18. Balkuv-Ulutin Ş Fibrinolytic system in atherosclerosis. Semin Thromb Hemesta. 12:1986;91-101.
19. Collen D, Johan-Vague I. Fibrinolysis and atherosclerosis Semin Thromb Hemost 1988;14:180-3.
20. Chobarian AV Pathophysiology of atherosclerosis. Am J Cardiol. 70:1992;3-7.
21. Metha J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: Correlation with age and serum triglyceride concentrations. JACC 1987;9(2):263-8.
22. Kruithoff EKO Plasminogen activator inhibitor type 1 and its relation to thrombosis. Med Razgl. 29(1):1990;43-52.
23. Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M, Suhan-Vague I. Increase in plasma concentration of plasminogen activator inhibitor fibrinogen, von willebrand factor, factor VIII: c and in erythrocyte sedimentation rate with age. Thromb Hemost 1986;55:330-2.
24. Simon DI, Fless GM, Scaro AM, Loscalzo J. Tissue type plasminogen activator binds to and is inhibited by surface bound lipoprotein (a) and low-density lipoprotein. Biochemistry 1991;30:6671-7.
25. Edelberg JM, Gonzales GM, Pizzo SU. Lipoprotein (a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989;28:2370-4.
26. Etingin OR, Hajjar DP, Hajjar KA, Harpez PO, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 1991;56:2459-65.
27. Seghatchian MJ, Samama MM. Hypercoagulability, inflammatory cytokines, disseminated intravascular coagulation and hyperfibrinolysis. In: Seghatchian MJ, Samama MM, Hecker SP, editors. Hypercoagulable States: Fundamental Aspects, Acquired Disorders and Congenital Thrombophilia. USA: CRC Press; 1996. p. 311-25.